Chester County News and Community Website
NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced $70 million in new capital commitments from Ligand Pharmaceuticals (Nasdaq: LGND) and Medtronic (NYSE: MDT), bolstering its efforts to …
Orchestra BioMed Secures $70 Million in Strategic Investments to Advance Cardiology Pipeline Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has presented key clinical insights into its atrioventricular interval modulation (AVIM) therapy for high-risk hypertension during the Congenital, Structural, and …
Orchestra BioMed Highlights AVIM Therapy’s Potential at CSI 2025 Meeting Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its financial results for the first quarter ended March 31, 2025, alongside significant regulatory and clinical milestones that …
Orchestra BioMed Reports Q1 2025 Financial Results and Advances Key Clinical Programs Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced significant advancements in the intellectual property backing its AVIM (Atrioventricular Interval Modulation) therapy pipeline. Over the past year, …
Orchestra BioMed Expands Patent Portfolio for AVIM Therapy, Gains FDA Breakthrough Designation Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has received FDA approval to move forward with its Virtue Trial, a pivotal clinical study designed to evaluate its next-generation …
Orchestra BioMed Secures FDA Clearance for Virtue Trial to Advance Coronary ISR Treatment Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its participation in the upcoming Jefferies Global Healthcare Conference, which will be held in New York, NY, on …
Orchestra BioMed to Present at Jefferies Global Healthcare Conference Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) will host a satellite symposium at the Heart Rhythm Society (HRS) 2025 Annual Meeting in San Diego to spotlight its …
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) announced that its atrioventricular interval modulation (AVIM) therapy has received Breakthrough Device Designation (BDD) from the U.S. Food and Drug …
Orchestra BioMed Secures FDA Breakthrough Device Designation for AVIM Therapy Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) has announced its financial results for 2024, alongside major updates on its clinical programs and corporate strategy. The company has demonstrated …
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy Read More NEW HOPE, PA — Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO), a biomedical technology company pioneering high-impact therapeutic solutions, announced its participation in several key investor conferences slated for late February and …
Orchestra BioMed to Participate in Upcoming Investor Conferences Read More